AfyaIndex — Drug Search

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

[Serratiopeptidase] Severe active hepatic disease / acute liver failure.
Hypersensitivity.
Chronic heavy alcohol use — use reduced maximum daily dose or avoid. [Aceclofenac] Active peptic ulcer / GI bleeding.
Severe heart failure.
NSAID-exacerbated respiratory disease (aspirin-sensitive asthma) for non-selective agents.
Third trimester pregnancy (ductus arteriosus, oligohydramnios — class warning).
Severe renal impairment for many agents.
Hypersensitivity to NSAIDs. [Paracetamol] Severe active hepatic disease / acute liver failure.
Hypersensitivity.
Chronic heavy alcohol use — use reduced maximum daily dose or avoid.

Precautions

[From component Paracetamol] Risk of severe hepatotoxicity in overdose.
Chronic high-dose use, malnutrition, enzyme-inducing drugs, and alcohol increase risk.
Check total daily intake from all sources.

02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.

Paediatric

Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.

Renal

Generally safe; prolonged high dose rare associations — prefer careful use in advanced CKD.

CrCl 0–120: Confirm renal dosing in product SmPC / primary label.

Hepatic

PRIMARY toxicity organ in overdose; therapeutic doses usually safe if daily limits respected.

03 Clinical use

Use, effects & interactions

Indications

Inflammation and pain in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
Clinical selection for Serratiopeptidase /Aceclofenac / Paracetamol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
Class context: Non-opioid analgesic / antipyretic.
Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

[Serratiopeptidase] [From component Diclofenac] GIT disturbances, GIT ulceration, headache, dizziness, vertigo, tinnitus, taste alteration, blood dyscrasia, renal, hepatic disorders. [Aceclofenac] Dyspepsia, nausea, fluid retention, raised BP.
Serious: peptic ulcer/bleed, AKI, heart failure exacerbation, severe skin reactions, bronchospasm, hepatitis (rare). [Paracetamol] Rare at therapeutic doses.
Serious: acute liver failure in overdose, rare severe skin reactions (SJS/TEN/AGEP).

Drug interactions

Open multi-drug checker ↗

First-line for mild–moderate pain and fever.
Calculate total daily exposure from all sources.
In overdose: timed levels + NAC per protocol — do not wait for symptoms.

04 Pharmacology

Mechanism & disposition

Combination product.

Inhibit COX↓ ProstaglandinsAnalgesia / anti-inflammatory

Read complete mechanism

Combination product. Component mechanism (Paracetamol): Inhibitors of cyclo-oxygenase [COX-1 and COX-2] enzyme that catalyzes the conversion of arachidonic acid to PGH2.

Onset

30–60 minutes oral

Duration

4–6 hours

Route

ORAL / RECTAL / IV

Metabolism

(glucuronidation/sulfation); toxic NAPQI pathway via CYP2E1 when pathways saturated or glutathione depleted.

Half-life

~2–3 h; prolonged in liver disease/overdose.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[Serratiopeptidase] Analgesic/antipyretic of choice in pregnancy when needed; use lowest effective dose/shortest duration. [Aceclofenac] Avoid in third trimester. Earlier pregnancy: use only if needed; prefer paracetamol first-line. [Paracetamol] Analgesic/antipyretic of choice in pregnancy when needed; use lowest effective dose/shortest duration.

Lactation

Compatible with breastfeeding at standard doses.

06 Kenya market

Brands & loaded prices

From—

Median—

Listings0

Brand	Manufacturer	Pack	Observed price
No reviewed brand listings are linked yet.

07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; PubChem; Component monographs (multi-source pipeline); Professional class pharmacology (Non-opioid analgesic / antipyretic)

Last reviewedNot recorded

EvidenceSource-linked

Open source document ↗

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.